Side-by-side comparison of AI visibility scores, market position, and capabilities
Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase 1 enrolling. Co-founded by Harvard's David Sinclair.
Life Biosciences is running the first FDA-cleared human trial of partial epigenetic reprogramming, using gene therapy to reverse vision loss caused by aging. Co-founded by Harvard aging biologist David Sinclair — whose research showed that aged retinal cells could be restored to youthful function by expressing Yamanaka factors — Life Biosciences received FDA clearance for its IND (Investigational New Drug) for ER-100 in optic neuropathies in January 2026 and closed an $80 million Series D in April 2026.
Raised $900M Series E at $11B valuation (Oct 2025). CEO projects ~$2B in 2026 sales. Launched women's health LLM (Feb 2026). Team USA LA28 Olympic partner.
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E financing at an $11 billion valuation in October 2025, reflecting the doubling of its revenue to $500 million in 2024 and a projected $1.5–2 billion in 2026 sales as it expands global distribution into India, UAE, and Latin America.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.